8-K Announcements
6Material company update
Mar 4, 2026·SEC
Material company update
Mar 3, 2026·SEC
Material company update
Feb 23, 2026·SEC
Ventyx Biosciences, Inc.(VTYX)Earnings, Financials & Key Ratios
VTYX•NASDAQ
$14.00
$999M mkt cap·Price updated May 1, 2026
AboutVentyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.Show more
- Revenue$0
- EBITDA-$147M+29.0%
- Net Income-$135M+30.0%
- EPS (Diluted)-1.97+40.3%
- ROE-54.27%+15.9%
- ROIC-50.33%+20.1%
- Debt/Equity0.04-17.1%
VTYX Key Insights
Ventyx Biosciences, Inc. (VTYX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 98 (top 2%)
✗Weaknesses
- ✗Shares diluted 17.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
VTYX Price & Volume
Ventyx Biosciences, Inc. (VTYX) stock price & volume — 10-year historical chart
Loading chart...
VTYX Growth Metrics
Ventyx Biosciences, Inc. (VTYX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM30.1%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM36.44%
Return on Capital
10 Years-52.33%
5 Years-52.33%
3 Years-53.67%
Last Year-57.18%
VTYX Recent Earnings
Ventyx Biosciences, Inc. (VTYX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q4 2025Latest
Nov 6, 2025EPS
$0.32
Est $0.45
+28.9%
Revenue
—
Q3 2025
Aug 7, 2025EPS
$0.38
Est $0.45
+15.6%
Revenue
—
Q2 2025
May 8, 2025EPS
$0.39
Est $0.48
+18.8%
Revenue
—
Q1 2025
Feb 27, 2025EPS
$0.41
Est $0.54
+24.1%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 6, 2025 | $0.32vs $0.45+28.9% | — |
| Q3 2025 | Aug 7, 2025 | $0.38vs $0.45+15.6% | — |
| Q2 2025 | May 8, 2025 | $0.39vs $0.48+18.8% | — |
| Q1 2025 | Feb 27, 2025 | $0.41vs $0.54+24.1% | — |
Based on last 12 quarters of dataView full earnings history →
VTYX Peer Comparison
Ventyx Biosciences, Inc. (VTYX) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARQT | 3.02B | 24.17 | -185.92 | 91.34% | -0.57% | -1.41% | 0.03 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 TARS | 2.76B | 64.76 | -40.73 | 146.71% | -9.02% | -14.19% | 0.27 | |
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 ABBV | 362.56B | 204.98 | 86.49 | 8.57% | 6.91% | 62.15% | ||
 LLY | 932.64B | 987.11 | 43.01 | 44.7% | 34.98% | 101.17% | 1.60 |
Compare VTYX vs Peers
Ventyx Biosciences, Inc. (VTYX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VTYX Income Statement
Ventyx Biosciences, Inc. (VTYX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - |
| Operating Expenses | 4.18M | 7.05M | 67.15M | 113.14M | 207.99M | 148.45M | 116.72M |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 628K | 684K | 8.67M | 25.4M | 32.23M | 31.45M | 29.03M |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 3.55M | 6.37M | 58.48M | 87.74M | 175.77M | 117M | 87.69M |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -4.18M▲ 0% | -7.05M▼ 68.7% | -67.15M▼ 852.4% | -113.14M▼ 68.5% | -207.99M▼ 83.8% | -148.45M▲ 28.6% | -116.72M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -68.66% | -852.44% | -68.49% | -83.84% | 28.63% | - |
| EBITDA | 0 | 0 | -67.12M | -112.67M | -207.05M | -147.1M | -115.67M |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | - | - | - | -67.87% | -83.78% | 28.95% | 29.87% |
| D&A (Non-Cash Add-back) | 4.18M | 7.05M | 30K | 470K | 941K | 1.35M | 1.05M |
| EBIT | -4.18M | -7.05M | -83.65M | -113.14M | -207.99M | -148.45M | -114.68M |
| Net Interest Income | -145.85K | -357.64K | -21K | 4.67M | 15.07M | 13.42M | 10.14M |
| Interest Income | 146 | 358 | 78K | 4.67M | 15.07M | 13.42M | 10.14M |
| Interest Expense | 146K | 358K | 99K | 0 | 0 | 0 | 0 |
| Other Income/Expense | -147K | -21.12M | -16.6M | 4.71M | 15.03M | 13.33M | 10.12M |
| Pretax Income | -4.33M▲ 0% | -28.17M▼ 551.1% | -83.75M▼ 197.2% | -108.43M▼ 29.5% | -192.96M▼ 78.0% | -135.12M▲ 30.0% | -106.61M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -4.47M▲ 0% | -28.17M▼ 529.9% | -83.75M▼ 197.2% | -108.43M▼ 29.5% | -192.96M▼ 78.0% | -135.12M▲ 30.0% | -106.61M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | - | -529.87% | -197.25% | -29.47% | -77.97% | 29.97% | 30.1% |
| Net Income (Continuing) | -4.33M | -28.17M | -83.75M | -108.43M | -192.96M | -135.12M | -106.61M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.29▲ 0% | -0.56▲ 75.5% | -1.69▼ 201.8% | -2.06▼ 21.9% | -3.30▼ 60.2% | -1.97▲ 40.3% | -1.50▲ 0% |
| EPS Growth % | - | 75.55% | -201.79% | -21.89% | -60.19% | 40.3% | 36.44% |
| EPS (Basic) | -2.29 | -0.56 | -1.69 | -2.06 | -3.30 | -1.97 | - |
| Diluted Shares Outstanding | 1.96M | 50.3M | 50.41M | 52.47M | 58.54M | 68.48M | 71.3M |
| Basic Shares Outstanding | 1.96M | 50.3M | 50.41M | 52.47M | 58.54M | 68.48M | 71.3M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
VTYX Balance Sheet
Ventyx Biosciences, Inc. (VTYX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 349K | 245K | 263.02M | 330.69M | 264.35M | 229.63M | 201.09M |
| Cash & Short-Term Investments | 309K | 244K | 258.58M | 317.94M | 252.22M | 217.32M | 192.64M |
| Cash Only | 309K | 244K | 70.79M | 64.82M | 51.58M | 27.26M | 31.97M |
| Short-Term Investments | 0 | 0 | 187.78M | 253.12M | 200.64M | 190.06M | 160.67M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 1M | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 12.75M | 12.13M | 11.3M | 8.46M |
| Total Non-Current Assets | 0 | 0 | 28.46M | 40.71M | 13.35M | 46.94M | 10.37M |
| Property, Plant & Equipment | 0 | 0 | 254K | 1.94M | 12.27M | 10.28M | 9.38M |
| Fixed Asset Turnover | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 28.15M | 38.67M | 0 | 35.62M | 36.6M |
| Other Non-Current Assets | 0 | 0 | 60K | 96K | 1.08M | 1.03M | 3.02M |
| Total Assets | 349K▲ 0% | 245K▼ 29.8% | 291.48M▲ 118872.2% | 371.4M▲ 27.4% | 277.69M▼ 25.2% | 276.56M▼ 0.4% | 211.47M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | 0.00x |
| Asset Growth % | - | -29.8% | 118872.24% | 27.42% | -25.23% | -0.41% | -79.45% |
| Total Current Liabilities | 631K | 1.4M | 12.28M | 16.36M | 22.27M | 12.78M | 11.26M |
| Accounts Payable | 362K | 1.1M | 4.66M | 6.43M | 5.76M | 3.13M | 993K |
| Days Payables Outstanding | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio | 0.55x | 0.17x | 21.41x | 20.21x | 11.87x | 17.97x | 17.97x |
| Quick Ratio | 0.55x | 0.17x | 21.41x | 20.21x | 11.87x | 17.97x | 17.97x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 3.85M | 29.5M | 0 | 1.15M | 11.51M | 9.74M | 8.84M |
| Long-Term Debt | 3.85M | 12.65M | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 1.15M | 11.51M | 9.74M | 37.19M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 16.85M | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 4.48M | 30.9M | 12.28M | 17.5M | 33.77M | 22.52M | 20.1M |
| Total Debt | 3.85M | 12.65M | 0 | 1.56M | 12.51M | 10.79M | 10.02M |
| Net Debt | 3.54M | 12.4M | -70.79M | -63.26M | -39.07M | -16.47M | -21.95M |
| Debt / Equity | - | - | - | 0.00x | 0.05x | 0.04x | 0.04x |
| Debt / EBITDA | - | - | - | - | - | - | -0.09x |
| Net Debt / EBITDA | - | - | - | - | - | - | 0.19x |
| Interest Coverage | -28.63x | -19.69x | -678.25x | - | - | - | - |
| Total Equity | -4.13M▲ 0% | -30.65M▼ 642.6% | 279.2M▲ 1010.8% | 353.89M▲ 26.8% | 243.92M▼ 31.1% | 254.04M▲ 4.1% | 191.36M▲ 0% |
| Equity Growth % | - | -642.59% | 1010.81% | 26.75% | -31.07% | 4.15% | -77.19% |
| Book Value per Share | -2.11 | -0.61 | 5.54 | 6.74 | 4.17 | 3.71 | 2.68 |
| Total Shareholders' Equity | -4.13M | -30.65M | 279.2M | 353.89M | 243.92M | 254.04M | 191.36M |
| Common Stock | 0 | 0 | 5K | 6K | 6K | 7K | 7K |
| Retained Earnings | -4.33M | -32.5M | -117.8M | -226.22M | -419.19M | -554.31M | -631.57M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | -58K | -1.12M | -50K | 157K | 223K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VTYX Cash Flow Statement
Ventyx Biosciences, Inc. (VTYX) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -2.64M | -6.2M | -38.65M | -98.77M | -166.52M | -130.87M | -130.87M |
| Operating CF Margin % | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -134.48% | -523.89% | -155.55% | -68.59% | 21.41% | 164.91% |
| Net Income | -4.33M | -28.17M | -83.75M | -108.43M | -192.96M | -135.12M | -106.61M |
| Depreciation & Amortization | 0 | 0 | 30K | 470K | 941K | 1.35M | 1.32M |
| Stock-Based Compensation | 198K | 45K | 2.73M | 16.57M | 28.59M | 22.93M | 19.37M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 896K | 21.12M | 38.32M | -2.23M | -8.89M | -9.47M | -6.04M |
| Working Capital Changes | 591K | 812K | 4.02M | -5.16M | 5.81M | -10.56M | 4.21M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 361K | 591K | 2.44M | 1.61M | -745K | -2.64M | -1.31M |
| Cash from Investing | 0 | 0 | -214.37M | -74.93M | 100.94M | -15.51M | 57.66M |
| Capital Expenditures | 0 | 0 | -262K | -275K | -514K | -241K | -114K |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 1.9M | 74.66K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -74.66K | 0 | 0 | 0 |
| Cash from Financing | 2.95M | 6.13M | 323.55M | 167.77M | 53.33M | 122.11M | 246K |
| Debt Issued (Net) | 2.95M | 6.13M | 450K | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1K | 2K | 1000K | 1000K | 1000K | 1000K | -179K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 68K |
| Other Financing | 0 | 0 | 65K | 2.37M | 4.92M | 466K | 425K |
| Net Change in Cash | 309K▲ 0% | -65K▼ 121.0% | 70.55M▲ 108633.8% | -5.97M▼ 108.5% | -12.27M▼ 105.4% | -24.32M▼ 98.3% | -29.8M▲ 0% |
| Free Cash Flow | -2.64M▲ 0% | -6.2M▼ 134.5% | -38.91M▼ 528.1% | -99.05M▼ 154.5% | -167.04M▼ 68.6% | -131.11M▲ 21.5% | -87.87M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - |
| FCF Growth % | - | -134.48% | -528.12% | -154.54% | -68.64% | 21.51% | 44.99% |
| FCF per Share | -1.35 | -0.12 | -0.77 | -1.89 | -2.85 | -1.91 | -1.91 |
| FCF Conversion (FCF/Net Income) | 0.59x | 0.22x | 0.46x | 0.91x | 0.86x | 0.97x | 0.82x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 1K | 3K | 0 | 0 | 0 | 0 |
VTYX Key Ratios
Ventyx Biosciences, Inc. (VTYX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -67.39% | -34.25% | -64.56% | -54.27% | -48.11% |
| Return on Invested Capital (ROIC) | - | -52.97% | -34.01% | -62.97% | -50.33% | -50.33% |
| Debt / Equity | - | - | 0.00x | 0.05x | 0.04x | 0.04x |
| Interest Coverage | -19.69x | -678.25x | - | - | - | - |
| FCF Conversion | 0.22x | 0.46x | 0.91x | 0.86x | 0.97x | 0.82x |
VTYX SEC Filings & Documents
Ventyx Biosciences, Inc. (VTYX) SEC filings — annual & quarterly reports (10-K, 10-Q)
VTYX Frequently Asked Questions
Ventyx Biosciences, Inc. (VTYX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Ventyx Biosciences, Inc. (VTYX) grew revenue by 0.0% over the past year. Growth has been modest.
Ventyx Biosciences, Inc. (VTYX) reported a net loss of $106.6M for fiscal year 2024.
Dividend & Returns
Ventyx Biosciences, Inc. (VTYX) has a return on equity (ROE) of -54.3%. Negative ROE indicates the company is unprofitable.
Ventyx Biosciences, Inc. (VTYX) had negative free cash flow of $87.9M in fiscal year 2024, likely due to heavy capital investments.
Explore More VTYX
Ventyx Biosciences, Inc. (VTYX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates